We are an European Clinical Research Organization specializing in early-phase studies in healthy volunteers, including first-in-human, SAD/MAD, PK/PD, and bioequivalence studies.
Based in the European Union, fully GCP compliant, with a dedicated Phase I unit of up to 40 participants.
Design and conduct of first-in-human, single and multiple dose studies in healthy volunteers or selected patient populations.
Safety-driven first-in-human trials with intensive medical monitoring and real-time data review for early decision making.
Structured single and multiple ascending dose studies to characterize safety, tolerability, and pharmacokinetics.
Bioavailability and bioequivalence trials for generics, reformulations, and fixed-dose combinations in line with EMA guidance.
Pharmacokinetic and pharmacodynamic investigations with intensive sampling, controlled conditions, and expert analysis.
Hybrid early-phase designs to accelerate proof-of-concept and support regulatory and development decisions.
Support for protocol development, ethics and authority submissions, and regulatory interactions in the EU.
Structured data capture, cleaning, and biostatistical analysis leading to clear, regulatory-ready clinical study reports.
CRS operates from Slovenia, a member state of the European Union, with convenient access to patients and healthy volunteers, and efficient connections to major European and global hubs.Our location offers an attractive environment for sponsors seeking cost-effective, high-quality early-phase research in the EU.
1996s
CRS d.o.o. established as a clinical research center in Slovenia.
20+ years
Continuous clinical research operations with focus on early-phase trials.
GCP-compliant processes
GCP-compliant processes and quality oversight aligned with EMA and national regulations.
Efficient EU regulatory pathways
Efficient EU regulatory pathways and streamlined startup for international sponsors.
